ROIVANT SCIENCES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.8 USD | -0.37% |
|
-0.09% | -3.83% |
Presenter SpeechCorinne Jenkins (Analysts)Everyone, and thanks so much to the team from Roivan...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Companyâs pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor in development across several IgG-mediated autoimmune indications; and brepocitinib, a TYK2/JAK1 inhibitor in late stage development for dermatomyositis, non-infectious uveitis, and other autoimmune conditions, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Sector
Pharmaceuticals
Calendar
11/08/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.8
USD
Average target price
16.78
USD
Spread / Average Target
+55.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.83% | 7.98B | |
| +51.99% | 798B | |
| -5.72% | 356B | |
| +18.94% | 328B | |
| +11.07% | 304B | |
| +16.96% | 244B | |
| +2.25% | 227B | |
| +11.15% | 216B | |
| +7.59% | 166B | |
| -3.65% | 157B |
- Stock Market
- Equities
- ROIV Stock
- News Roivant Sciences Ltd.
- Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08
